Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144

Rhea-AI Filing Summary

Enliven Therapeutics director Joseph Lyssikatos reported proposed sales of common stock under a Form 144 notice. The filing lists 25,000 shares associated with Jefferies as the broker and multiple past dispositions totaling 130,000 shares across February–March 2026 with aggregate proceeds shown per trade. The filing documents routine resale activity by an insider; timing and additional proceeds treatment are shown by the listed trade dates.

Insights

Equity Securities Analyst

Form 144 records proposed insider sales and several recent dispositions by the reporting person.

The filing lists 25,000 shares tied to Jefferies as the broker and a sequence of sales on 02/06/2026, 02/18/2026, 02/19/2026, 02/25/2026, and 03/31/2026

These entries show cash proceeds per trade; the filing is a regulatory notice of resale rather than a corporate action. Subsequent SEC filings or market disclosures would clarify whether these sales were part of a plan or ad hoc dispositions.

Key Figures

Proposed shares to be sold: 25,000 shares Past dispositions (count): 130,000 shares Proceeds — 02/18/2026 sale: $1,317,640.00 +4 more

7 metrics

Proposed shares to be sold 25,000 shares listed with Jefferies as broker

Past dispositions (count) 130,000 shares aggregate of five sales on Feb–Mar 2026

Proceeds — 02/18/2026 sale $1,317,640.00 sale of 50,000 shares on 02/18/2026

Proceeds — 02/19/2026 sale $520,217.41 sale of 20,000 shares on 02/19/2026

Proceeds — 03/31/2026 sale $965,774.35 sale of 25,000 shares on 03/31/2026

Proceeds — 02/06/2026 sale $145,219.10 sale of 5,000 shares on 02/06/2026

Proceeds — 02/25/2026 sale $144,613.70 sale of 5,000 shares on 02/25/2026

Key Terms

Form 144, Founder shares, Resale

3 terms

Form 144 regulatory

"reported proposed sales of common stock under a Form 144 notice"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Founder shares financial

"Founder shares | Enliven Therapeutics"

Founder shares are the ownership stakes given to the people who start a company, often with extra voting power or protections compared with ordinary shares. For investors, they matter because founders’ control and incentives influence decisions about strategy, hiring, and whether the company sells or stays independent — like a family that keeps majority voting rights in a household decision. High founder ownership can mean stable leadership but also a risk that outside shareholders have less influence.

Resale regulatory

"Securities To Be Sold ... Securities Sold During The Past 3 Months"

Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	25000	1060000.00	59000000	04/30/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder shares	Enliven Therapeutics			25000	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/06/2026	5000	145219.10
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/18/2026	50000	1317640.00
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/19/2026	20000	520217.41
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/25/2026	5000	144613.70
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	03/31/2026	25000	965774.35

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for ELVN indicate?

The Form 144 indicates an insider proposed resale of 25,000 shares and records multiple past dispositions. It lists trade dates and per‑trade proceeds for sales in Feb–Mar 2026, showing regulatory notice of resale activity.

Who is the reporting person on the ELVN Form 144?

Joseph Lyssikatos is listed as the reporting person. The filing provides an address and identifies him in connection with the reported founder shares and resale transactions.

How many shares were sold by the insider in recent months per the filing?

The filing lists five recent sales totaling 130,000 shares executed between 02/06/2026 and 03/31/2026. Each sale also shows an aggregate dollar amount for proceeds next to the trade date.

Which broker is named for the proposed sale in the Form 144?

The filing names Jefferies LLC at 520 Madison Ave as the broker associated with the listed 25,000 shares to be sold and indicates Nasdaq as the market.

Do the Form 144 entries state whether sales were under a trading plan?

The excerpt does not state whether the sales were made under a pre‑arranged trading plan. The filing lists trade dates and proceeds but does not include a 10b5‑1 plan reference in the provided text.